Does ENZALUTAMIDE Cause Malignant neoplasm progression? 4,696 Reports in FDA Database
Prostate Health & Male Vitality — Naturally
ProstaVive: better flow, better sleep, better energy. 180-day guarantee.
According to the FDA Adverse Event Reporting System (FAERS), 4,696 reports of Malignant neoplasm progression have been filed in association with ENZALUTAMIDE (Xtandi). This represents 9.5% of all adverse event reports for ENZALUTAMIDE.
4,696
Reports of Malignant neoplasm progression with ENZALUTAMIDE
9.5%
of all ENZALUTAMIDE reports
1,482
Deaths
695
Hospitalizations
How Dangerous Is Malignant neoplasm progression From ENZALUTAMIDE?
Of the 4,696 reports, 1,482 (31.6%) resulted in death, 695 (14.8%) required hospitalization, and 32 (0.7%) were considered life-threatening.
Is Malignant neoplasm progression Listed in the Official Label?
This adverse event is not currently listed in the official FDA drug label for ENZALUTAMIDE. However, 4,696 reports have been filed with the FAERS database.
What Other Side Effects Does ENZALUTAMIDE Cause?
Fatigue (8,891)
Death (6,680)
Prostatic specific antigen increased (3,731)
Asthenia (3,589)
Drug ineffective (3,468)
Hot flush (3,144)
Decreased appetite (3,069)
Nausea (2,898)
Dizziness (2,776)
Diarrhoea (2,470)
What Other Drugs Cause Malignant neoplasm progression?
PEMBROLIZUMAB (10,111)
NIVOLUMAB (9,363)
CARBOPLATIN (4,177)
EVEROLIMUS (3,789)
PACLITAXEL (3,484)
LETROZOLE (3,445)
IPILIMUMAB (3,296)
FULVESTRANT (3,221)
LENVATINIB (2,929)
OSIMERTINIB (2,920)
Which ENZALUTAMIDE Alternatives Have Lower Malignant neoplasm progression Risk?
ENZALUTAMIDE vs EPCORITAMAB
ENZALUTAMIDE vs EPCORITAMAB-BYSP
ENZALUTAMIDE vs EPERISONE
ENZALUTAMIDE vs EPHEDRINE
ENZALUTAMIDE vs EPINASTINE